Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Camizestrant + PF-07220060 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Camizestrant | AZD-9833|AZD9 833|AZD9833|AZ-14066724 | Hormone - Anti-estrogens 31 | Camizestrant (AZD9833) is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1024-1024). | |
| PF-07220060 | PF 07220060|PF07220060|Atirmociclib | CDK4 Inhibitor 19 | PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07427394 | Phase II | Camizestrant + PF-07220060 | Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer (SERENA-1b) | Not yet recruiting | USA | GBR | 0 |